The agenda includes:
Preparation of positions on the evaluation of drugs:
- Libtayo (cemiplimab) under a drug programme “Treatment of patients with advanced basal cell carcinoma of the skin with cemiplimab (ICD-10 C44)”,
- Verzenios (abemaciclib) under a drug programme “Treatment of HR+, HER2- early breast cancer with high risk of recurrence with abemaciclib”.
Preparation of an opinion on the use of the M-TYPER and M-TYPER reagents for the diagnosis of tuberculosis and other mycobacterioses based on mass spectrometry technology.
Preparation of an opinion on the draft health policy programme of the local government unit „Programme for early detection of hearing and vision impairments in children residing in the City of Opole for 2023-2026.”